Morethan 240 companies across the globe claim to have the required capabilities tooffer variety of services on a contract basis, working at different scales ofoperation, for a wide range of ophthalmic APIs and drug FDFs, claims RootsAnalysis
Owingto various reasons, such as growing manufacturing demand, need for specializedfacilities, equipment and operational expertise, and high costs of developmentassociated with certain drugs / therapies, a number of ophthalmic drugdevelopers have demonstrated a preference to outsource certain aspects of drugdevelopment and production operations to contract service providers.
TheUSD 1.7 billion financial opportunity (by 2030) within the Ophthalmic Drugs Contract ManufacturingMarket hasbeen analyzed across the following segments:
RootsAnalysis has done a detailed study on Ophthalmic Drugs Contract ManufacturingMarket: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms(Ophthalmic Drops, Emulsions, Gels, Injections, Lotions, Ointments,Suspensions, and Tablets / Capsules), 2020-2030, covering key aspects of theindustry’s evolution and identifying potential future growth opportunities.
GetDetailed Analysis: https://www.rootsanalysis.com/reports/view_document/ophthalmic-drugs-cmo/294.html
KeyMarket Insights
· Over 240 companies across the globe claim tohave the required capabilities to offer variety of services on a contractbasis, working at different scales of operation, for a wide range of ophthalmicAPIs and drug FDFs
· The market is fragmented, featuring thepresence of both established players and small firms based in differentgeographies that claim to be capable of manufacturing ophthalmic products
· Presently, majority of the CMOs are offeringservices for ophthalmic drug FDFs packaged in a variety of formats; populartypes of containers include glass / plastic bottles, ointment tubes andampoules / vials
· In order to acquire competencies across thesupply chain and cater to evolving needs of sponsors, companies haveestablished presence across different regions, having been certified by variousregulatory authorities
· Several players involved in this domain aresteadily expanding their capabilities in order to enhance their respectiveservice portfolios and maintain a competitive edge
· In the past few years, over 10,700 trials,enrolling approximately 4.6 million patients, suffering from a wide range ofchronic eye conditions, have been registered across the globe by differentsponsors
· Most of the installed, global ophthalmic drugmanufacturing capacity belongs to larger and more established CMOs, accountingfor over 80% of available capacity across various geographies
· The demand for manufacturing services forophthalmic drug products is expected to increase in the coming years; webelieve stakeholders may have to expand their respective capacities to ensureconsistent supply
· We expect ophthalmic drug developers tocontinue to outsource their development and manufacturing operations in theshort to mid-term, causing service-based revenues to grow at an annualized rateof over 8%
· In the long-term, the projected opportunityis anticipated to be well distributed across various packaging formats, scalesof operation and sizes of contract service providers
· Eminent representatives from prominentophthalmic drug contract manufacturing companies confirm the importance ofoutsourcing, highlighting prevalent and anticipated trends within this domain
Typeof product
· Ophthalmic API
· Ophthalmic drug FDF
Typeof FDF manufactured
· Solid
· Semi-solid
· Liquid / suspension
Typeof primary packaging
· Ampoule / vial
· Glass / plastic bottle
· Ointment tube
· Blister packing
· Other forms
Scaleof manufacturing
· Clinical
· Commercial
Companysize
· Small
· Mid-sized
· Large
· Very large
Targetdisease indication
· Age-related macular degeneration
· Dry eye
· Glaucoma
· Other disease segments
Keygeographical regions
· North America (US, Canada and Mexico)
· Europe (UK, Germany, France, Spain, Italy andrest of Europe)
· Asia-Pacific (India, China, Japan, Australiaand rest of Asia-Pacific)
· Rest of the world
Requestfor Customization: https://www.rootsanalysis.com/reports/294/request-customization.html
TheOphthalmic Drugs Contract Manufacturing Market: Focus on Active PharmaceuticalIngredients and Finished Dosage Forms (Ophthalmic Drops, Emulsions, Gels,Injections, Lotions, Ointments, Suspensions, and Tablets / Capsules), 2020-2030report features the following companies, which we identified to be key playersin this domain:
· Akorn
· Akums
· Bal Pharma
· Catalent
· Cayman Chemical
· Entod Pharmaceuticals
· Farmigea
· Glenmark Pharmaceuticals
· Indiana Ophthalmics
· Lomapharm
· Medichem
· Pillar5 Pharma
· Recipharm
· Salvat
· Sterling Pharmaceutical Services
· Sunways India
Tableof Contents
1. Preface
2. Executive Summary
3. Introduction
4. Current Market Landscape
5. Company CompetitivenessAnalysis
6. Ophthalmic Drugs ContractManufacturing in North America: Company Profiles
7. Ophthalmic Drugs ContractManufacturing in Europe: Company Profiles
8. Ophthalmic Drugs ContractManufacturing in Asia-Pacific: Company Profiles
9. Clinical Trial Analysis
10. Capacity Analysis
11. Demand Analysis
12. Market Forecast
13. Case Study: Comparisonof Small Molecule and Large Molecule Ophthalmic Drugs / Therapies
14. SWOT Analysis
15. Survey Analysis
16. Executive Insights
17. Future GrowthOpportunities
18. Appendix 1: List ofOphthalmic Medical Device Contract Manufacturers
19. Appendix 2: TabulatedData
20. Appendix 3: List ofCompanies and Organizations
GetLatest PDF Sample of this Report:
https://www.rootsanalysis.com/reports/294/request-sample.html
AboutRoots Analysis
RootsAnalysis is one of the fastest growing marketresearch companies, sharing fresh and independent perspectives in thebio-pharmaceutical industry. The in-depth research, analysis and insights aredriven by an experienced leadership team which has gained many years ofsignificant experience in this sector. If you’d like help with your growingbusiness needs, get in touch at info@rootsanalysis.com
ContactInformation
RootsAnalysis Private Limited
GauravChaudhary
+1(415) 800 3415
Gaurav.Chaudhary@rootsanalysis.com
Alsohave a Look on Our Upcoming Research Reports
Soft Tissue Sarcoma: Pipeline Review,Developer Landscape and Competitive Insights, 2021-2031
Spinal Muscular Atrophy Market, 2021-2031
